Digestive disease interventions最新文献_第9页

Microwave Ablation of Hepatocellular Carcinoma and Liver Metastases: Challenges, Opportunities, and Future Directions 微波消融治疗肝细胞癌和肝转移:挑战、机遇和未来方向

Digestive disease interventions Pub Date : 2022-01-21 DOI: 10.1055/s-0041-1741521

Lindsay M. Stratchko, E. K. Koepsel, T. Ziemlewicz, E. Knott, J. Hinshaw, S. Wells, P. Laeseke, Fred T. Lee Jr

引用次数: 0

Interventional Techniques to Support Enteral Nutrition 介入技术支持肠内营养

Digestive disease interventions Pub Date : 2022-01-20 DOI: 10.1055/s-0042-1742295

Simon Long, D. Fernando, Christina Boyd, J. Katrivesis, Harold Park

引用次数: 1

Comparison of Outcomes with Triple-Regimen versus Double-Regimen Transarterial Chemoembolization 三方案与双方案经动脉化疗栓塞的疗效比较

Digestive disease interventions Pub Date : 2022-01-20 DOI: 10.1055/s-0042-1756460

A. Smolock, Osmani Deochand, W. Rilling, P. Patel, E. Hohenwalter, S. White, M. Scheidt

引用次数: 0

Sclerotherapy of Symptomatic Nonparasitic Splenic Cysts: Excellent Long-Term Treatment Response' 硬化疗法治疗症状性非寄生虫性脾囊肿:长期疗效优异

Digestive disease interventions Pub Date : 2022-01-14 DOI: 10.1055/s-0041-1742245

M. Dölle, H. Wedemeyer, M. Gebel, A. Potthoff, S. Zender

{"title":"Sclerotherapy of Symptomatic Nonparasitic Splenic Cysts: Excellent Long-Term Treatment Response'","authors":"M. Dölle, H. Wedemeyer, M. Gebel, A. Potthoff, S. Zender","doi":"10.1055/s-0041-1742245","DOIUrl":"https://doi.org/10.1055/s-0041-1742245","url":null,"abstract":"\u0000 Background Splenic cysts are rare and occur in 0.5 to 2% of the population. They are usually asymptomatic and do not require therapy. In case of symptomatic nonparasitic splenic cysts, potential therapy includes partial splenectomy or laparoscopic cyst de-roofing as well as ultrasound-guided sclerotherapy with 1% polidocanol or 10% sodium chloride (NaCl) as an interventional alternative. So far, single-session sclerotherapy of symptomatic nonparasitic cysts is recommended only if clear-transparent cyst fluid is aspirated.\u0000 Materials and Methods We report a case series of 17 patients with symptomatic macroscopically turbid nonparasitic splenic cyst fluid who underwent ultrasound-guided fine needle sclerotherapy with either polidocanol ± 10% NaCl (n = 12) or 10% NaCl alone (n = 5) and a follow-up of a maximum of 12 years after first intervention. Clinical, sonographic, and laboratory chemistry data were recorded at baseline and during the follow-up.\u0000 Results The mean follow-up time was 43.65 ± 40.18 months. At the end of the follow-up, a 79% reduction of cyst size was achieved. The maximum size reduction in the polidocanol group was 76 ± 18% and 84 ± 21% in the sodium chloride group (p >0.05). At the end of follow-up, 15 out of the 17 patients did not have any further symptoms. Despite the cystic fluid being turbid, it was hardly possible to detect a microbiological superinfection.\u0000 Conclusion Sclerotherapy of splenic cysts leads to a significant size regression in all patients, independent of the sclerotherapy agent used with fewer systemic toxic side effects of polidocanol treatment. It was shown that in a tertiary care center with significant experience, sclerotherapy of splenic cysts is also safe and successful and can lead to a drastic regression of cyst size and symptoms. This shows that interventional therapy is a good alternative to surgical procedures.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89954008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

State of the Art: Contrast Enhanced 4D Ultrasound to Monitor or Assess Locoregional Therapies 最新进展:造影增强四维超声监测或评估局部治疗

Digestive disease interventions Pub Date : 2022-01-11 DOI: 10.1055/s-0041-1741520

M. Tantawi, S. Shamimi-Noori, C. Shaw, J. Eisenbrey

{"title":"State of the Art: Contrast Enhanced 4D Ultrasound to Monitor or Assess Locoregional Therapies","authors":"M. Tantawi, S. Shamimi-Noori, C. Shaw, J. Eisenbrey","doi":"10.1055/s-0041-1741520","DOIUrl":"https://doi.org/10.1055/s-0041-1741520","url":null,"abstract":"Abstract Locoregional therapies (LRTs) are an essential management tool in the treatment of primary liver cancers or metastatic liver disease. LRTs include curative and palliative modalities. Monitoring treatment response of LRTs is crucial for maximizing benefit and improving clinical outcomes. Clinical use of contrast-enhanced ultrasound (CEUS) was introduced more than two decades ago. Its portability, cost effectiveness, lack of contraindications and safety make it an ideal tool for treatment monitoring in numerous situations. Two-dimensional dynamic CEUS has been proved to be equivalent to the current imaging standard in the guidance of LRTs, assessment of their adequacy, and detection of early tumor recurrence. Recent technical advances in ultrasound transducers and image processing have made 3D CEUS scanning widely available on most commercial ultrasound systems. 3D scanning offers a broad multiplanar view of anatomic structures, overcoming many limitations of two-dimensional scanning. Furthermore, many ultrasound systems provide real-time dynamic 3D CEUS, also known as 4D CEUS. Volumetric CEUS has shown to perform better than 2D CEUS in the assessment and monitoring of some LRTs. CEUS presents a valid alternative to the current imaging standards with reduced cost and decreased risk of complications. Future efforts will be directed toward refining the utility of 4D CEUS through approaches such as multi-parametric quantitative analysis and machine learning algorithms.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85879497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Laparoscopic Liver Resection: Surgical Techniques 腹腔镜肝切除术:外科技术

Digestive disease interventions Pub Date : 2022-01-11 DOI: 10.1055/s-0041-1742153

B. Sullivan, R. Wolf, Z. Jutric

引用次数: 0

Sarcopenia of Cirrhosis and the Therapeutic Potential of Transjugular Intrahepatic Portosystemic Shunt Creation 肝硬化肌肉减少症和经颈静脉肝内门静脉系统分流术的治疗潜力

Digestive disease interventions Pub Date : 2022-01-10 DOI: 10.1055/s-0041-1742214

B. Schlansky, K. Farsad

引用次数: 0

Endoscopic Operating Platforms and Advancements 内镜手术平台和进展

Digestive disease interventions Pub Date : 2022-01-07 DOI: 10.1055/s-0041-1740599

I. Sethi, Amy Rosenbluth

引用次数: 0

Gallbladder Cryoablation: Clinical and Technical Considerations 胆囊冷冻消融:临床和技术考虑

Digestive disease interventions Pub Date : 2022-01-04 DOI: 10.1055/s-0041-1742101

H. McGregor

{"title":"Gallbladder Cryoablation: Clinical and Technical Considerations","authors":"H. McGregor","doi":"10.1055/s-0041-1742101","DOIUrl":"https://doi.org/10.1055/s-0041-1742101","url":null,"abstract":"Abstract As many as 500,000 cholecystectomies are performed per year in the United States. Frail patients are at higher risk from cholecystectomy, with reported postoperative complication and mortality rates as high as 31 and 5% in patients older than 75 years. Percutaneous cholecystostomy drainage is commonly employed in high-risk patients with cholecystitis, with over 12,000 cases performed annually. Cholecystostomy, however, is not a definitive treatment, with up to 30% of patients having a recurrent episode of cholecystitis within 4 months after tube removal. Gallbladder cryoablation has emerged as a minimally invasive procedure that achieves transmural gallbladder wall necrosis in a single session resulting in gallbladder fibrosis and involution. Early clinical data have been promising, with reported technical success of 86% and clinical success of 100% at up to 500 days of follow-up. Several challenges and unknowns remain, however, including optimal patient selection and procedural technique, the potential need for adjunct procedures to occlude the cystic duct, the implications of the immunostimulatory effects of cryoablation, and the impact of the presence of gallstones on outcomes. This article reviews the rationale behind gallbladder cryoablation, updates early clinical outcomes, and discusses the challenges that remain for the adoption of the technique for the treatment of benign gallbladder disease.","PeriodicalId":91014,"journal":{"name":"Digestive disease interventions","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79153201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variceal Hemorrhage: Decompression, Obliteration, or Both? 静脉曲张出血:减压，闭塞，还是两者兼而有之?

Digestive disease interventions Pub Date : 2022-01-04 DOI: 10.1055/s-0041-1742100

B. McCafferty, H. E. Khudari, A. Salei, A. Gunn

引用次数: 0